Lifestyle Determinants and Metabolic Compensation in Pregnancies Complicated by Type 1 Diabetes: A Synthesis of the ENDIA Study and Recent Evidence
Posted inClinical Updates Diabetes & Endocrinology news OB/GYN & Women's Health

Lifestyle Determinants and Metabolic Compensation in Pregnancies Complicated by Type 1 Diabetes: A Synthesis of the ENDIA Study and Recent Evidence

This review analyzes the lifestyle patterns of pregnant women with type 1 diabetes, synthesizing findings from the ENDIA study with recent evidence on nutritional adequacy, islet autoimmunity, and the molecular mechanisms of metabolic compensation.
Transitioning to Tubeless Automated Insulin Delivery: Clinical Insights from the RADIANT Trial and Contemporary Management of Type 1 Diabetes
Posted inClinical Updates Diabetes & Endocrinology news

Transitioning to Tubeless Automated Insulin Delivery: Clinical Insights from the RADIANT Trial and Contemporary Management of Type 1 Diabetes

This review synthesizes the landmark RADIANT trial findings, demonstrating the efficacy of transitioning patients from multiple daily injections to tubeless automated insulin delivery, while integrating broader evidence on genetic susceptibility and metabolic comorbidity management.
Addressing the Human Element: Why Psychological Barriers and Educational Gaps Limit the Efficacy of Diabetes Decision Support Systems
Posted inDiabetes & Endocrinology news Psychiatry

Addressing the Human Element: Why Psychological Barriers and Educational Gaps Limit the Efficacy of Diabetes Decision Support Systems

A randomized trial reveals that while automated decision support systems show marginal overall glycemic benefits in type 1 diabetes, personalized informative feedback significantly aids users with lower baseline knowledge. Success depends heavily on addressing diabetes-related distress and hypoglycemia worry.
Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D
Posted inDiabetes & Endocrinology Internal Medicine news

Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D

A post-hoc analysis demonstrates that baseline insulin secretion identifies responders to abatacept in Stage 1 T1D. High-secretors experienced a 15.8-month delay in disease progression and a 54% reduction in risk, providing the first evidence of successful immune intervention in the earliest stage of the disease.
High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial
Posted inDiabetes & Endocrinology news Pediatrics

High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial

The POInT trial demonstrated that high-dose daily oral insulin does not prevent islet autoantibodies in infants at high genetic risk for type 1 diabetes. Despite its safety, the primary endpoint was not met, though genotype-specific interactions suggest a need for more personalized prevention strategies.
Video Consultations for Insulin Pump-Treated Type 1 Diabetes: Non-Inferior Glycemic Control with Nuanced Patient Outcomes
Posted inDiabetes & Endocrinology Internal Medicine news

Video Consultations for Insulin Pump-Treated Type 1 Diabetes: Non-Inferior Glycemic Control with Nuanced Patient Outcomes

A 52-week RCT demonstrates that video consultations achieve comparable Time in Range (TiR) to physical visits for T1D patients on insulin pumps. While the intervention improved HbA1c and treatment satisfaction, it was associated with an inferior impact on patient quality of life.
Beyond the Alarm: Does CGM Truly Restore Hypoglycemia Awareness in Older Adults with Type 1 Diabetes?
Posted inDiabetes & Endocrinology Internal Medicine news

Beyond the Alarm: Does CGM Truly Restore Hypoglycemia Awareness in Older Adults with Type 1 Diabetes?

This post hoc analysis of the WISDM study evaluates whether 52 weeks of continuous glucose monitoring (CGM) improves impaired awareness of hypoglycemia (IAH) in older adults. While severe events decreased, physiological awareness remained largely unchanged, revealing critical limitations in current IAH assessment tools.
Inhaled Insulin for Pediatric Type 1 Diabetes: Analyzing the INHALE-1 Trial Results and Clinical Implications
Posted inDiabetes & Endocrinology news Pediatrics

Inhaled Insulin for Pediatric Type 1 Diabetes: Analyzing the INHALE-1 Trial Results and Clinical Implications

The INHALE-1 trial evaluated inhaled technosphere insulin in children. While it narrowly missed the primary HbA1c noninferiority margin, the study demonstrated improved patient satisfaction, reduced weight gain, and a favorable safety profile, suggesting its potential as a needle-free alternative for select pediatric patients.
Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety
Posted inDiabetes & Endocrinology Nephrology news

Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety

The FINE‑ONE Phase III trial found finerenone reduced urinary albumin-to-creatinine ratio (UACR) by 25% versus placebo in adults with type 1 diabetes and chronic kidney disease over six months, with safety broadly consistent with prior type 2 diabetes trials and a manageable hyperkalemia signal.